

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |   |
|--|--|--|---|
| (51) International Patent Classification 5 :<br><br>A61F 13/00   |  | A1   | (11) International Publication Number: <b>WO 91/19470</b><br><br>(43) International Publication Date: 26 December 1991 (26.12.91) |
| <p>(21) International Application Number: PCT/US91/04095<br/>(22) International Filing Date: 14 June 1991 (14.06.91)<br/><br/>(30) Priority data:<br/>539,990 14 June 1990 (14.06.90) US</p> <p>(71) Applicant: VITAPHORE CORPORATION [US/US];<br/>1505 O'Brien Drive, Menlo Park, CA 94025 (US).</p> <p>(72) Inventors: BOOTMAN, Matthew ; 2536 Hampton Avenue,<br/>Redwood City, CA 94061 (US). YAMAMOTO, Ronald ;<br/>484 15th Avenue, Atherton, CA 94025 (US).</p> <p>(74) Agents: KENNEY, J., Ernest; Bacon &amp; Thomas, 625 Slaters Lane, 4th Floor, Alexandria, VA 22314 (US) et al.</p> |  | <p>(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published<br/><i>With international search report.</i></p> |   |
| (54) Title: POLYURETHANE-BIOPOLYMER COMPOSITE  |  |  |   |
| (57) Abstract  |  |  |   |
| <p>A method is provided for preparing a drug delivery material and device comprising cross-linking a biological polymer with a cross-linking agent and loading the cross-linked biopolymer with a bioactive agent. Preferred embodiments are disclosed wherein the drug delivery material is used in a catheter securing, drug delivery device, in a wound dressing, and in a wound dressing for percutaneous catheters.</p>   |  |  |   |

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria                  | ES | Spain                                    | MG | Madagascar               |
| AU | Australia                | FI | Finland                                  | ML | Mali                     |
| BB | Barbados                 | FR | France                                   | MN | Mongolia                 |
| BE | Belgium                  | GA | Gabon                                    | MR | Mauritania               |
| BF | Burkina Faso             | GB | United Kingdom                           | MW | Malawi                   |
| BG | Bulgaria                 | GN | Guinea                                   | NL | Netherlands              |
| BJ | Benin                    | GR | Greece                                   | NO | Norway                   |
| BR | Brazil                   | HU | Hungary                                  | PL | Poland                   |
| CA | Canada                   | IT | Italy                                    | RO | Romania                  |
| CF | Central African Republic | JP | Japan                                    | SD | Sudan                    |
| CG | Congo                    | KP | Democratic People's Republic<br>of Korea | SE | Sweden                   |
| CH | Switzerland              | KR | Republic of Korea                        | SN | Senegal                  |
| CI | Côte d'Ivoire            | LI | Liechtenstein                            | SU | Soviet Union             |
| CM | Cameroon                 | LK | Sri Lanka                                | TD | Chad                     |
| CS | Czechoslovakia           | LU | Luxembourg                               | TC | Togo                     |
| DE | Germany                  | MC | Monaco                                   | US | United States of America |

be replaced within a short period of time. One situation in which it is desirable to have a drug delivered over a prolonged period of time without removal of the delivery device is the case of

5 delivery of drugs at a wound site around a percutaneous medical device.

Moreover, it is desirable, particularly when dealing with delivery of bioactive agents which are natural products, such as growth factors, that the polymeric

10 matrix from which the drug is delivered be tailored for optimal drug delivery rate. It is difficult to do this when the drug to be delivered is a biological macromolecule, such as an enzyme or surface receptor, since specialized binding functionalities with proper  
15 charge density, orientation, hydrophobic domains, etc. are not readily synthesized into synthetic polymers to release the biological macromolecule at a desired controlled rate.

It is thus an object of the present invention to  
20 provide a polymeric delivery vehicle for controlled release of bioactive agents, particularly biological macromolecules, which is formed of a foam composite of a biopolymer and a synthetic polymer.

It is another object of the present invention to  
25 provide drug delivery devices, particularly wound dressings, containing such polymeric delivery vehicles for controlled release of antimicrobial and/or wound-healing agents to aid in the wound healing process.

30 It is another object of the present invention to provide a catheter-securing and drug delivery device which is easily used which contains a pad comprising a biopolymer which serves as a delivery vehicle for

controlled release of a bioactive agent to the catheter wound site.

These and other objects of the invention will be apparent from the following description and appended

5 claims, and from practice of the invention.

SUMMARY OF THE INVENTION

The present invention provides a method for preparing a polymeric delivery vehicle for controlled release of a bioactive agent. The method comprises the steps  
10 of cross-linking a biopolymer which contains chemically reactive confunctionalities which react with a cross-linking reagent, where the cross-linking reagent is a polyurethane or polyurethane urea having isocyanate side groups and/or end groups, to form a  
15 cross-linked biopolymer having an effective affinity for the bioactive agent; optionally, forming the cross-linked biopolymer into a desired shape; then contacting the cross-linked biopolymer with a bioactive agent to reversibly bind the bioactive  
20 agent to the biopolymer to form the polymeric delivery vehicle. Alternatively, the bioactive agent is bound to the biopolymer before treatment with the cross-linking agent. By effective binding affinity it is meant that the bioactive agent can be bound  
25 (noncovalently) to sites in the biopolymer; then, when in use in contact with skin and/or bodily fluids, or other fluids, a substantial amount of the bioactive agent will be released from the biopolymer, with release continuing for an extended period of  
30 time.

In a preferred embodiment of the present invention, the polymeric delivery vehicle is used in a catheter-securing and drug delivery device. The device comprises an elastomeric pad having a radial slit

extending from the edge of the pad to a central point proximate to the center of the pad. The pad comprises a cross-linked biopolymer and a bioactive reagent reversibly bound thereto, wherein the

5 bioactive reagent is releasable from the cross-linked biopolymer in a controlled manner to a wound or to the skin. The device further comprises a reinforced, flexible, water vapor permeable membrane adhesively attached to the pad which extends beyond the edge of

10 the pad on all sides thereof, thereby forming a flange surrounding the pad. At least the edges of the exposed bottom surface of the membrane is coated with an adhesive material for affixing the device to the skin. The membrane has another radial slit

15 extending from the edge of the membrane, through the membrane toward the central point of the pad, which is colinearally aligned with the slit in the pad. Finally, the device optionally comprises a reinforced, flexible, water vapor permeable tab

20 affixed to the upper surface of the membrane and located proximate to one side of the pad wherein one surface of the tab is adhesively coated and the tab has dimensions sufficient to cover the pad when the tab is folded for adhesive attachment to the upper

25 surface of the pad.

In another preferred embodiment the polymeric delivery vehicle in the form of an elastomeric pad is used as a wound dressing. The pad may be secured upon a wound by an adhesive water-vapor film over the

30 pad which adheres to the skin area surrounding the wound.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a graph of the weight of chlorhexidene gluconate released versus time from two types of

polyurethane-modified biopolymers and from a polyurethane control polymer.

Figure 2 is a graph of drug loading (silver ion) as a function of amount of biopolymer (gelatin) in a 5 gelatin-polyurethane composite sponge.

Figure 3 is a graph of a typical drug (silver ion) release rate from a composite of polyurethane - 22% gelatin.

10 Figure 4 is a perspective view of a preferred embodiment of a catheter-securing and drug delivery device according to the present invention.

Figure 5 is a side view of the device shown in Figure 4.

15 Figure 6 is a perspective view of a catheter-securing device accommodating a catheter.

Figure 7 is a plan view of a wound dressing according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

20 The polymeric delivery vehicle for controlled release of a bioactive agent according to the present invention may be formed by treating a biopolymer with a cross-linking agent whereby the cross-linking agent is simultaneously polymerized and formed into cross-linking moieties with the biopolymers. The preferred 25 cross-linking agents are polyisocyanate-terminated polyurethane or polyurethane urea pre-polymers which are known in the art. If water is used as a solvent the reaction of the polyurethane or polyurethane urea cross-linking agent via the isocyanate side and/or 30 end groups of the cross-linking agent is carbon

dioxide which results in a foam material. If non-protic solvents are used, a solid (unfoamed) polymeric composite will result. A material may be cast into films, slabs or molded into desired shapes.

5 The biopolymers which are to be treated with a cross-linking agent according to the present invention include, but are not limited to proteins, peptides and polysaccharides, such as:

|     | <u>Biopolymer</u>         | <u>Biological</u>      |
|-----|---------------------------|------------------------|
| 10  | <u>Source</u>             |                        |
| 1.  | Polygalacturonic acid     | Citrus peels           |
| 2.  | Hydroxypropyl cellulose   | Wood                   |
| 3.  | Hydroxyethyl cellulose    | Wood                   |
| 4.  | Heparin                   | Porcine                |
| 15  | intestine                 |                        |
| 5.  | Collagen                  | Animal tendon,<br>hide |
| 6.  | Gelatin                   | Animal hide            |
| 7.  | Carboxymethyl cellulose   | Wood                   |
| 20  | 8. Pectin                 | Citrus peels           |
| 9.  | Algin                     | Kelp                   |
| 10. | Ethyl cellulose           | Wood                   |
| 11. | Glycosaminoglycan         | Animal Tissues         |
| 12. | Chitin                    | Arthropods             |
| 25  | 13. Other polysaccharides | ---                    |

Preferred biopolymers are gelatin, collagen, and polysaccharides, such as modified cellulose, as, for example, hydroxyethylcellulose.

30 The thickness of the polymeric matrix may be varied as desired, depending upon the desired pharmaceutical dosage and duration of delivery. Ordinarily, a suitable matrix thickness will be in a range of about 0.1 to 1.0 centimeters (cm).

35 The ratio of cross-linking agent to biopolymer will depend in part on the particular biopolymer and the bioactive agent with which it is intended to be used. It will be understood that mixtures of different biopolymers may also be utilized. However,

generally, it will be useful to employ a weight ratio of cross-linking agent to biopolymer of from about 20:1 to about 1:1. It will be realized that suitable polymerization initiators may be utilized to initiate 5 the polymerization reaction, which include, but are not limited to azobisisobutylnitrile, peroxide initiators, such as benzoyl peroxide, isopropyl peroxide, and the like. Although polyurethane and polyurethane ureas are the preferred cross-linking 10 agents, other cross-linking agents may be suitable, such as butylene diacrylate, ethylene dimethacrylate, divinyl benzene, ethylene glycoldimethacrylates, tetraethylene glycoldimethacrylate, methylbisacrylamate, as well as other cross-linking 15 agents which will cross-link molecules with reactive protic groups.

It will be realized from the teachings herein that the degree of cross-linking, thickness and/or shape of the cross-linked biopolymer, and the degree of 20 porosity (if any) are all parameters which may be controlled to attain a desired release profile of the bioactive agent from the cross-linked biopolymer. Furthermore, the biopolymer may be chemically modified to change its binding affinity for a 25 selected bioactive agent. For example, hydroxyethyl cellulose may be partially methylated to reduce the number of cross-linking sites and/or potential chelating sites, depending upon whether the cross-linking is performed before or after the bioactive 30 agent is impregnated into the biopolymer.

The shape of the cross-linked biopolymer may be formed by molding during cross-linking or, after cross-linking, it may be formed into a desired shape by casting or cutting. The cross-linked biopolymer 35 will then be loaded with the desired bioactive

agent(s), which is believed to occur by ionic binding involving ionic sites on the biopolymer, with the desired bioactive agent, which may be antimicrobial drugs or macromolecules such as growth factors,

5 antibacterial agents, antispasmodic agents, or any other active biological bioactive agent, such as adrenergic agents such as ephedrine, desoxyephedrine, phenylephrine, epinephrine and the like, cholinergic agents such as physostigmine, neostigmine and the

10 like, antispasmodic agents such as atropine, methantheline, papaverine and the like, tranquilizers and muscle relaxants such as fluphenazine, chlorpromazine, trifluopromazine, mephenesin, meprobamate and the like, antidepressants like

15 amitriptyline, nortriptyline, and the like, antihistamines such as diphenhydramine, dimenhydrinate, tripeleannamine, perphenazine, chlorprophenazine, chlorprophenpyradimine and the like, hypotensive agents such as rauwolfia,

20 reserpine and the like, cardioactive agents such as bendroflumethiazide, flumethiazide, chlorothiazide, aminotrate, propranolol, nadolol, procainamide and the like, angiotensin converting enzyme inhibitors such as captopril and enalapril, bronchodilators

25 such as theophylline, steroids such as testosterone, prednisolone, and the like, antibacterial agents, e.g., sulfonamides such as sulfadiazine, sulfamerazine, sulfamethazine, sulfisoxazole and the like, antimalarials such as chloroquine and the like,

30 antibiotics such as the tetracyclines, nystatin, streptomycin, cephadrine and other cephalosporins, penicillin, semi-synthetic penicillins, griseofulvin and the like, sedatives such as chloral hydrate, phenobarbital and other barbiturates, glutethimide,

35 antitubercular agents such as isoniazid and the like, analgesics such as aspirin, acetaminophen, phenylbutazone, propoxyphene, methadone, meperidine

and the like, etc. These substances are frequently employed either as the free compound or in a salt form, e.g., acid addition salts, basic salts like alkali metal salts, etc. Other therapeutic agents 5 having the same or different physiological activity can also be employed in the pharmaceutical preparations within the scope of the present invention. Typically, the bioactive agent dissolved in a suitable solvent will be contacted with the 10 cross-linked biological polymer by immersion. The loading of the biopolymer may be readily determined based upon the uptake of the biopolymer of the bioactive agent.

15 In a preferred method for forming the loaded cross-linked biopolymer, the bioactive agent is dissolved in water at a suitable concentration, typically about 1-2% by weight, and the cross-linked biological polymer is immersed therein for a period of about 240 minutes. At ambient temperature (about 20-25°C), the 20 biopolymer is then extracted from the solvent, allowed to air dry or is lyophilized, and is then ready for use.

25 Alternatively, the cross-linked biopolymer may be loaded with the bioactive agent, then dried, then cut to a suitable form for use.

In another preferred method, the bioactive agent and biopolymer are dissolved in an aqueous solvent before cross-linking and the bioactive agent is bound to the biopolymer. Typical agent: biopolymer weight ratios 30 are in the range of about 1:100 to 5:100 in solution. The biopolymer is then cross-linked by treatment with the cross-linking agent.

**SUBSTITUTE SHEET**

-10-

It will be realized that the biopolymer material may be modified, for example, so as to be made more hydrophilic or hydrophobic to adjust for suitable binding properties to the bioactive agent. Such

5 modification may be performed by, for example, esterification of acid groups in the biopolymer prior to cross-linking, thus making the biopolymer more hydrophobic.

10 The general reactions for a typical treatment of a biopolymer having protic groups (-HX) with polyisocyanate are shown below in Table 1.

TABLE 1  
General reaction of polyisocyanate with acidic group




15




X = -CO<sub>2</sub>, -S, -O, -N

20 Polyurethane prepolymer




FOAMING:



**SUBSTITUTE SHEET**

-11-



5

Referring to the figures, in Figure 1 there is shown a graph of drug release of chlorhexidine gluconate from two biopolymers as compared to a contrast polymer. The control biopolymer is polyurethane (10). One of the test foams is polyurethane cross-linked (10wt.%) collagen and polyurethane cross-linked (10wt.%) hydroxyethyl cellulose (HEC). The foams and control were soaked in a 2% solution of chlorhexidine gluconate (CHXG) for the same period of time. To measure the drug efflux from each of the biopolymers, each was placed in a large reservoir of physiological saline and the bathing medium was changed daily to maintain sink conditions. As shown in Figure 1, the drug was released quickly and completely from the control foam by the fifth day. A more controlled release was achieved in the cross-linked hydroxyethyl cellulose, with the drug still being slowly released after 13 days. Release from HEC can extend beyond 13 days, but in that test the experiment was stopped after 13 days. A more extended release profile is shown in the cross-linked collagen, with drug release occurring even up to 17 days, when the experiment was stopped. Moreover, it can be seen from the graph that a greater amount of CHXG was released from the two test samples than from the control. Although the HEC test was halted after 13 days, its CHXG release curve was still on an upward slope, and it already had released about as much CHXG as the control.

35 In Figure 2 there is shown a graph of drug loading, where the drug is a silver ion, as a function of the

amount of gelatin (biopolymer) in a gelatin-polyurethane composite sponge. It can be seen that without the biopolymer (0% gelatin) there is essentially no binding taking place whereas the drug 5 binding increases with increasing amount of biopolymer present in the composite.

Referring to Figure 3 there is shown a graph of a chemical drug release rate (of silver ion) from a composite of polyurethane - 22% gelatin. It can be 10 seen that there is a surge of drug release during the first day, then in the second day, continuing to the tenth day (the end of the particular test) there is a relatively constant rate of release of the drug from the composite.

15 Referring to Figure 4, there is shown a preferred embodiment of the present invention in a catheter-securing and drug delivery device. The device comprises a reinforced, flexible, water vapor permeable membrane 10, a portion of which is upturned 20 as a flap 11. Membrane 10 may be made of any water vapor permeable synthetic polymer such as a polyurethane or polyester reinforced with thread. At least the edges of the bottom surface of membrane 10 (including flap 11) are coated with an adhesive (not 25 shown). Alternatively, the entire bottom surface of membrane 10 (including flap 11) may be coated with an adhesive. On the bottom surface of the membrane 10, about centrally located thereunder, is affixed an elastomeric pad 16. The elastomeric pad 16 will be a 30 cross-linked, biological polymer loaded with a bioactive agent modified according to the present invention. Preferably, the biopolymer comprises a cross-linked hydroxyethyl cellulose and the bioactive agent is an antimicrobial agent such as chlorhexidene 35 gluconate. Both the membrane 10 and the pad 16 are

adapted with slit 18, with the slit in pad 16 being collinear with the slit in the membrane 10. Both slits terminate at a point 19 located proximate to the center of the pad 16. At point 19 the pad 16 and 5 membrane 10 will surround a catheter (not shown) whereby the membrane 10 and pad 16 serve as a catheter fixing device. The pad 16 additionally serves as a drug delivery component for delivering antimicrobial agents or other agents to the wound 10 caused by the catheter. Thus, pad 16 may be used without membrane 10, in an alternative embodiment, in which case at least the edges of the bottom surface of pad 16 will be coated, impregnated, or otherwise adapted with an adhesive material.

15 Returning to FIG. 4, on the upper surface of the membrane 10 and adjacent to the central point 19 is shown an optional pillow 17 which, may also be made of a cross-linked biological polymer loaded with an antimicrobial agent according to the present 20 invention. The purpose of the pillow 17 is for receiving and supporting the side of the catheter (not shown), since catheters may extend from the skin surface at an oblique angle. The extension of the catheter from the skin may be rested upon the pillow 25 17. Adjacent to the slit 18 is flap 14 which may be made of the same reinforced, flexible, water vapor permeable material as membrane 10 and is affixed to membrane 10. The flap 14 is shown in an open position, therefore the reinforced, flexible, water 30 vapor permeable membrane is on the underside and not seen in the figure. The flap 14 is coated with an adhesive (not shown) and the adhesive is protected by a removable protecting layer (such as, paper or plastic) 15. Once the catheter is in place at 35 central port 19 the flap 14 is folded over the catheter and, by removal of layer 15, the flap 14 is

adhesively attached over a portion of the slit 18, the pillow 17, a portion of the catheter (not shown) as well as over a portion of the upper surface of the membrane 10. This serves not only to affix the 5 catheter but also to maintain the slit 18 in a closed position.

In an alternative embodiment, still referring to FIG. 4, the device may be used as a wound dressing for use with percutaneous catheters without the 10 catheter-securing feature of flap 14 (and protecting layer 15) by assembling the device without these items. Without flap 14, the pillow 17 may also be optionally deleted.

Before use, the bottom adhesively coated surfaces of 15 membrane 10 (including flap 11) are protected, as shown, by three removable layers 12, 13a, 13b (made, for example, of paper or plastic). First, layer 12 is removed and the catheter is pulled through slit 18 until it is engaged at central point 19. The 20 adhesive portion of flap 11 is then secured to the skin. Then layers 13a and 13b are removed and the remainder of the membrane 10 is secured to the skin. Finally, the catheter is securely placed onto pillow 17 (if present) and flap 14 is folded over, and, 25 after removal of layer 15, flap 14 is secured over the catheter and membrane 10.

A particular advantage of the device shown in Figure 4 is that it is light, easily used and disposable, as opposed to other catheter-securing 30 devices which accommodate complex mechanical parts, some of which must be sterilized for re-use. Another advantage of the device shown in Figure 4, particularly when used in conjunction with the cross-linked biopolymer according to the present invention,

The following examples are presented for the purpose of illustration and are not intended to limit the invention in any way.

EXAMPLE 1

- 5 To a 2.5% (w/v) solution of hydroxyethylcellulose is added (1:1 weight ratio) anhydrous polyisocyanate-terminated urethane pre-polymer. The mixed composite is placed in an open vessel, and cured for about 30 minutes at R.T. to form a "bun". The bun is cut into
- 10 a desired shape and placed in a 2.5% (v/v) solution of 22% chlorhexidine Gluconate (adjusted at pH 8.0 with ammonium hydroxide. After incubation for 4 hours, the sponge is removed, frozen and lyophilized.

EXAMPLE 2

- 15 In an aqueous solution of gelatin (120 g/100 ml water), adjusted to pH 7.6, is added silver nitrate to the desired silver ion concentration, and the mixture is stirred for at least 4 hours in a brown glass bottle. The pH is adjusted to 7.2 and stirring
- 20 is continued for 2 hours. The 36 parts of anhydrous polyisocyanate-terminated urethane prepolymer is added per 64 parts of the gelatin-silver solution. The mixture is placed in an open vessel and allowed to cure for 30-45 minutes at R.T. to form a bun. The
- 25 bun is cut into desired shapes and washed in deionized water.

The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the

30 described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the scope of the invention is to be limited solely with respect to the appended claims and equivalents.

## WHAT IS CLAIMED IS:

1. A method for preparing a polymeric delivery vehicle for controlled-release of a bioactive agent comprising the steps of
  - 5 treating with a cross-linking agent a biopolymer containing chemically reactive functionalities which react with said cross-linking reagent, said cross-linking agent selected from the group consisting of polyurethanes and polyurethane
  - 10 ureas having isocyanate side groups and/or end groups, to form a cross-linked biopolymer having an effective binding affinity for said bioactive agent; optionally, forming said cross-linked biopolymer into a desired shape;
  - 15 contacting said cross-linked biopolymer with said bioactive agent under conditions sufficient to reversibly bind at least a portion of said bioactive agent to said cross-linked biopolymer to form said polymeric delivery vehicle.
- 20 2. A method for preparing a polymeric delivery vehicle for controlled-release of a bioactive agent comprising the steps of
  - contacting a biopolymer containing chemically reactive functionalities which react with a cross-
  - 25 linking agent with a bioactive agent under conditions sufficient to reversibly bind at least a portion of said bioactive agent to said biopolymer;
  - optionally, forming said biopolymer into a desired shape; and
- 30 treating said biopolymer with a cross-linking agent selected from the group consisting of polyurethanes and polyurethane ureas having isocyanate side groups and/or end groups, to form said polymeric delivery vehicle.

3. A method according to Claim 1 or 2 wherein said step of cross-linking said biopolymer is conducted in the presence of a protic solvent whereby a gaseous side product is evolved, whereby said cross-linked 5 biopolymer is formed as a foam.
4. A method according to Claim 1 or 2 wherein said step of cross-linking is conducted in the presence of a nonprotic solvent whereby said cross-linked biopolymer is formed as an essentially non-porous 10 solid.
5. A method according to Claim 1 or 2 wherein said step of forming said cross-linked biopolymer into a desired shape is performed by casting said cross-linked biopolymer as a film in a suitable solvent and 15 evaporating said solvent.
6. A method according to Claim 1 or 2 wherein said step of forming said cross-linked biopolymer into a desired shape is performed by molding.
7. A method according to Claim 1 or 2 wherein said 20 cross-linked biopolymer is contacted with a solution comprising said bioactive agent.
8. A method according to Claim 1 or 2 wherein said biopolymer is selected from the group consisting of gelatin, collagen, and polysaccharides.
- 25 9. A method according to Claim 1 or 2 wherein said bioactive agent comprises chlorhexidine.
10. A method according to Claim 8 wherein said polysaccharide is a modified cellulose or glycosaminoglycan.

11. A method according to Claim 1 or 2 wherein said biopolymer is selected from the group consisting of a protein and/or peptide.
12. A method according to Claim 11 wherein said 5 biopolymer further comprises silver ions chelated to said protein and/or peptide.
13. A method according to Claim 1 or 2 wherein said biopolymer is chemically modified to tailor its binding affinity for said bioactive agent to a 10 desired control release profile.
14. A method according to Claim 1 or 2 wherein said bioactive agent is an anti-microbial agent.
15. A method according to Claim 1 or 2 wherein said bioactive agent is a pharmacological drug.
- 15 16. A method according to Claim 1 or 2 wherein said bioactive agent is a growth factor.
17. A percutaneous catheter wound dressing and drug-delivery device comprising  
an elastomeric pad having a first radial slit  
20 extending from the edge of said pad to a central point proximate to the center of said pad, said pad comprising a cross-linked biopolymer and at least one bioactive agent reversibly bound to said cross-linked biopolymer, said bioactive agent being releasable  
25 from said cross-linked biopolymer in a controlled manner to a wound or to skin when said pad is placed in contact with said wound or skin.
18. A device according to Claim 17 further comprising a reinforced, flexible, water-vapor  
30 permeable membrane adhesively attached to said pad,

-20-

said membrane extending beyond the edge of said pad on all sides thereof, thereby forming a flange surrounding said pad; at least the edges of the exposed bottom surface of said membrane being coated 5 with an adhesive material for affixing to the skin; said membrane having a second radial slit extending from the edge of said membrane through said membrane toward said central point of said pad, said second slit being colinearally aligned with said first slit 10 in said pad.

19. A device according to Claim 18 further comprising a reinforced, flexible, water-vapor permeable tab affixed to the upper surface of said membrane, said tab located proximate to one side of 15 said pad having an adhesively coated surface, said tab having dimensions sufficient to cover said pad when said tab is folded for adhesive attachment to the upper surface of said pad.

20. A device according to Claim 19 further 20 comprising a cushion means located adjacent to said central point on said upper surface of said pad and affixed to said pad, said cushion means comprising said cross-linked biopolymer and containing said bioactive agent, said cushion means serving to fill 25 the space formed between said pad and a catheter inserted through said central point when said tab is folded in adhesive contact with said pad and said catheter.

21. A device according to Claim 18 further 30 comprising removable pull tabs protecting the exposed adhesive material on said membrane.

22. A device according to Claim 19 further comprising a removable pull tab protecting the

**SUBSTITUTE SHEET**

exposed adhesive surface of said tab affixed to the upper surface of said membrane.

23. A device according to Claim 18 wherein the entire bottom surface of said membrane is coated with 5 said adhesive material.

24. A device according to Claim 18, 19 or 20 wherein said biopolymer is selected from the group consisting of gelatin, collagen, and polysaccharides.

25. A device according to Claim 18, 19 or 20 10 wherein said bioactive agent comprises chlorhexidine.

26. A device according to Claim 18, 19 or 20 wherein said biopolymer comprises a modified cellulose or glycosaminoglycan.

27. A device according to Claim 18, 19 or 20 15 wherein said biopolymer is selected from the group consisting of a protein and/or a peptide.

28. A device according to Claim 18, 19 or 20 wherein said biopolymer is chemically modified to tailor its binding affinity for said bioactive agent 20 to a desired control release profile.

29. A device according to Claim 18, 19 or 20 wherein said bioactive agent is an anti-microbial agent.

30. A device according to Claim 18, 19 or 20 25 wherein said bioactive agent is a pharmacological drug.

31. A device according to Claim 18, 19 or 20 wherein said bioactive agent is a growth factor.

-22-

32. A wound dressing and drug-delivery device for controlled-release of a bioactive agent comprising a cross-linked biopolymer and a bioactive agent reversibly bound thereto.
- 5 33. A wound dressing according to Claim 32 wherein said biopolymer comprises collagen or gelatin and said bioactive agent comprises silver ions.
34. A wound dressing according to Claim 32 further comprising a flexible water vapor permeable film
- 10 containing an adhesive skin contacting surface for affixing said wound dressing to the skin.
35. A wound dressing according to Claim 32 wherein said bioactive agent comprises a peptide and/or protein.
- 15 36. A wound dressing according to Claim 35 wherein said protein is a growth factor.
37. A wound dressing according to Claim 32 wherein said bioactive agent comprises an immune-modulating factor.




FIG. 1.

SUBSTITUTE SHEET





FIG. 2.

SUBSTITUTE SHEET



SUBSTITUTE SHEET




FIG. 4.




FIG. 5.





FIG. 6.

SUBSTITUTE SHEET



**SUBSTITUTE SHEET**

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04095

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5): A61F 13/00

U.S. CL. 424/449

## II. FIELDS SEARCHED

- Minimum Documentation Searched 7

| Classification System | Classification Symbols |
|-----------------------|------------------------|
| U.S.                  | 424/449, 448, 447, 78  |

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched 8

## III. DOCUMENTS CONSIDERED TO BE RELEVANT 9

| Category * | Citation of Document, 11 with indication, where appropriate, of the relevant passages 12  | Relevant to Claim No. 13 |
|------------|---|--------------------------|
| Y          | US, A, 4,814,182 (GRAHAM ET AL)<br>21 MARCH 1989; See column 2 for cross-linked<br>biopolymer with drug and column 3 for usage. | 1-37                     |

### \* Special categories of cited documents: 10

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

29 JULY 1991

Date of Mailing of this International Search Report

23 AUG 1991

International Searching Authority

ISA/US

Signature of Authorized Officer

*Leon R. Horne*  
Leon R. Horne

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**